Therefore, we hypothesized that two major nuclear NAD+-dependent mechanisms underlie the tumor-promoting role of NMNAT1 in ActD-treated osteosarcoma cells: PARP and SIRT activities. This evidence concerns the gene NMNAT1 and osteosarcoma.